OKYO Pharma (LON:OKYO) Stock Price Down 11.1%
OKYO Pharma (LON:OKYO) Stock Price Down 11.1%
OKYO Pharma Limited (LON:OKYO – Get Rating)'s stock price was down 11.1% during mid-day trading on Tuesday . The company traded as low as GBX 2 ($0.02) and last traded at GBX 2 ($0.02). Approximately 417,748 shares traded hands during mid-day trading, an increase of 83% from the average daily volume of 227,957 shares. The stock had previously closed at GBX 2.25 ($0.03).
週二午盤,Okyo Pharma Limited(LON:OKYO-GET Rating)股價下跌11.1%。該公司股價最低跌至2英鎊(0.02美元),最新報2英鎊(0.02美元)。午盤交易中,約有417,748股股票易手,較日均成交量227,957股增加83%。該股此前收盤價為2.25英鎊(0.03美元)。
OKYO Pharma Stock Up 28.4 %
Okyo Pharma股價上漲28.4%
The business's 50 day moving average price is GBX 2.86 and its 200-day moving average price is GBX 2.98. The company has a debt-to-equity ratio of 1.65, a current ratio of 3.17 and a quick ratio of 2.65. The company has a market cap of £39.72 million and a P/E ratio of -5.39.
該業務的50日移動均線價格為2.86英鎊,200日移動均線價格為2.98英鎊。該公司的債務權益比為1.65,流動比率為3.17,速動比率為2.65。該公司市值為3972萬GB,本益比為-5.39。
About OKYO Pharma
大代製藥公司簡介
(Get Rating)
(獲取評級)
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
Okyo Pharma Limited是一家臨床前生物製藥公司,致力於為英國患有炎症性眼病和眼痛的患者開發治療藥物。其主導產品包括用於治療乾眼病的OK-101。該公司還在開發OK-201,一種牛腎上腺髓質,脂化肽臨床前類似物,用於治療神經性眼痛。
Further Reading
進一步閱讀
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
- Lucid Motors面臨的現實可能會給看漲的看法蒙上陰影
- 機構將Rite Aid的股票跌至谷底
- 這就是為什麼你應該避開聯盟快遞的反彈
- 維京治療公司股票為何暴漲
- 耐克公司業績和前景走高
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《大代醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Okyo Pharma和相關公司的最新新聞和分析師評級的每日簡要摘要。